Photo of Toni K. Choueiri,  MD

Toni K. Choueiri, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Toni K. Choueiri, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Attending Physician, Solid Tumor Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

DF/HCC ASSOCIATIONS

  • Member, Center Scientific Council

Publications

Powered by Harvard Catalyst
  • Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, Palma NA, Stein MN, Johnson A, Squillace R, Elvin JA, Chmielecki J, Yelensky R, Yakirevich E, Lipson D, Lin DI, Miller VA, Stephens PJ, Ali SM, Ross JS. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. Eur Urol 2015. PubMed
  • Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol 2015; 33:330.e19-25. PubMed
  • Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer 2015. PubMed
  • Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezolosky MD, Viswanathan VB, Choueiri TK, Sweeney CJ, Trinh QD, Nguyen PL. Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer 2015. PubMed
  • Sun M, de Velasco G, Trinh QD, Choueiri TK. Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction. Eur Urol 2015. PubMed
  • Trinh QD, Nguyen PL, Leow JJ, Dalela D, Chao GF, Mahal BA, Nayak M, Schmid M, Choueiri TK, Aizer AA. Cancer-specific mortality of asian americans diagnosed with cancer: a nationwide population-based assessment. Journal of the National Cancer Institute 2015. PubMed
  • Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw 2015; 13:772-99. PubMed
  • Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S. Differential expression of PD-L1 between primary and metastatic sites in clear cell Renal Cell Carcinoma. Cancer Immunol Res 2015. PubMed
  • Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015; 94:228-237. PubMed
  • Grünwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2015; 67:952-8. PubMed
  • Ghatalia P, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2015. PubMed
  • Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Risk of Prostate Cancer Mortality in Men with a History of Prior Cancer. BJU Int 2015. PubMed
  • Ghatalia P, Morgan CJ, Choueiri TK, Rocha P, Naik G, Sonpavde G. Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015; 94:136-145. PubMed
  • Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015; 16:426-35. PubMed
  • Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DY. Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Clin Genitourin Cancer 2015; 13:150-5. PubMed
  • Sonpavde G, Jones BS, Bellmunt J, Choueiri TK, Sternberg CN. Future Directions and Targeted Therapies in Bladder Cancer. Hematol Oncol Clin North Am 2015; 29:361-376. PubMed
  • Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2015; 13:e79-85. PubMed
  • Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J. Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. Clin Genitourin Cancer 2015; 13:185-92. PubMed
  • McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA, Atkins MB. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015. PubMed
  • Balan M, Mier Y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression. J Biol Chem 2015; 290:8110-20. PubMed
  • Ghatalia P, Je Y, Mouallem NE, Nguyen PL, Trinh QD, Sonpavde G, Choueiri TK. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2015; 93:257-76. PubMed
  • Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015; 16:293-300. PubMed
  • Krajewski KM, Nishino M, Ramaiya NH, Choueiri TK. RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy. AJR Am J Roentgenol 2015; 204:W282-8. PubMed
  • Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C, Benson P, Ho TH, Pandite L, de Souza P, Powles T, Motzer RJ. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clin Cancer Res 2015; 21:1071-7. PubMed
  • McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015. PubMed
  • Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J. HER2 as a target in invasive urothelial carcinoma. Cancer Med 2015. PubMed
  • Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Incidence and Predictors of Upgrading and Upstaging Among 10,000 Contemporary Patients with Low-risk Prostate Cancer. J Urol 2015. PubMed
  • Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Netw 2015; 13:151-9. PubMed
  • Sammon JD, McKay RR, Kim SP, Sood A, Sukumar S, Hayn MH, Hu JC, Kibel AS, Nguyen PL, Peabody JO, Saad F, Sun M, Varda B, Menon M, Choueiri TK, Trinh QD. Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology 2015; 85:343-9. PubMed
  • Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer? Am J Med 2015. PubMed
  • Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer 2015; 3:3. PubMed
  • Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME, Choueiri TK, Van Allen E, Rosenberg J. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS ONE 2015; 10:e0124711. PubMed
  • Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Efstathiou JA, Hyatt AS, Graham PL, Trinh QD, Hu JC, Nguyen PL. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw 2015; 13:61-8. PubMed
  • Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. Eur Urol 2014. PubMed
  • Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014; 2:1132-41. PubMed
  • Sonpavde G, Pond GR, Mullane S, Qu AQ, Di Lorenzo G, Federico P, Necchi A, Rosenberg JE, Bellmunt J, Choueiri TK. Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clin Genitourin Cancer 2014. PubMed
  • Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw 2014; 12:1629-49. PubMed
  • Sammon JD, Abdollah F, Reznor G, Pucheril D, Choueiri TK, Hu JC, Kim SP, Schmid M, Sood A, Sun M, Kibel AS, Nguyen PL, Menon M, Trinh QD. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. Eur Urol 2014. PubMed
  • Ziehr DR, Mahal BA, Aizer AA, Hyatt AS, Beard CJ, D׳Amico AV, Choueiri TK, Elfiky A, Lathan CS, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol 2014. PubMed
  • Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D'Andrea A, Garraway LA, Rosenberg JE. Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. 2014; 4:1140-53. PubMed
  • Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2014. PubMed
  • Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, , Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014; 26:319-30. PubMed
  • Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, Choueiri TK, Karam JA, Jones JO. RNA-seq Reveals Aurora Kinase Driven-mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Mol Cancer Res 2014. PubMed
  • Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. Curr Treat Options Cardiovasc Med 2014; 16:335. PubMed
  • Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol 2014. PubMed
  • Ravi P, Karakiewicz PI, Roghmann F, Gandaglia G, Choueiri TK, Menon M, McKay RR, Nguyen PL, Sammon JD, Sukumar S, Varda B, Chang SL, Kibel AS, Sun M, Trinh QD. Mental health outcomes in elderly men with prostate cancer. Urol Oncol 2014. PubMed
  • Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy with Excess Cardiac-Specific Mortality in Men with Prostate Cancer. BJU Int 2014. PubMed
  • Schmid M, Ghani KR, Choueiri TK, Sood A, Kapoor V, Abdollah F, Chun FK, Leow JJ, Olugbade K, Sammon JD, Menon M, Kibel AS, Fisch M, Nguyen PL, Trinh QD. An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. BJU Int 2014. PubMed
  • Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2014. PubMed
  • Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 2014; 84:386-92. PubMed
  • Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014. PubMed
  • Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK. Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014. PubMed
  • Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma. Clin Genitourin Cancer 2014. PubMed
  • Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK. Adrenocortical carcinoma: The management of metastatic disease. Crit Rev Oncol Hematol 2014. PubMed
  • Aizer AA, Falit B, Mendu ML, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Trinh QD, Alexander BM, Nguyen PL. Cancer-Specific Outcomes Among Young Adults Without Health Insurance. J Clin Oncol 2014. PubMed
  • Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, Schwartz JD, Thompson JA. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer 2014. PubMed
  • Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol 2014; 65:1086-92. PubMed
  • Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. 2014. PubMed
  • Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med 2014. PubMed
  • Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D׳Amico AV, Martin NE, Lathan C, Kim SP, Trinh QD, Nguyen PL. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol 2014. PubMed
  • Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Trinh QD, Hu JC, Nguyen PL. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 2014; 120:1532-9. PubMed
  • Dahal A, Bellows BK, Sonpavde G, Tantravahi SK, Choueiri TK, Galsky MD, Agarwal N. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. Am J Clin Oncol 2014. PubMed
  • Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. J Clin Oncol 2014. PubMed
  • Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Racial Disparities in Prostate Cancer-Specific Mortality in Men With Low-Risk Prostate Cancer. Clin Genitourin Cancer 2014. PubMed
  • Fay AP, Signoretti S, Choueiri TK. MET as a Target in Papillary Renal Cell Carcinoma. Clin Cancer Res 2014. PubMed
  • Aizer AA, Chen MH, Parekh A, Choueiri TK, Hoffman KE, Kim SP, Martin NE, Hu JC, Trinh QD, Nguyen PL. Refusal of Curative Radiation Therapy and Surgery Among Patients With Cancer. Int J Radiat Oncol Biol Phys 2014. PubMed
  • Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int 2014; 113:E137-43. PubMed
  • Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. 2014. PubMed
  • Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int 2014; 113:E67-74. PubMed
  • Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370:1769-70. PubMed
  • Krajewski KM, Franchetti Y, Nishino M, Fay AP, Ramaiya N, Van den Abbeele AD, Choueiri TK. 10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study. Oncologist 2014. PubMed
  • Gandaglia G, Sammon JD, Chang SL, Choueiri TK, Hu JC, Karakiewicz PI, Kibel AS, Kim SP, Konijeti R, Montorsi F, Nguyen PL, Sukumar S, Menon M, Sun M, Trinh QD. Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. J Clin Oncol 2014. PubMed
  • Seible DM, Gu X, Hyatt AS, Beard CJ, Choueiri TK, Efstathiou JA, Miyamoto DT, Mitin T, Martin NE, Sweeney CJ, Trinh QD, Beckman JA, Basaria S, Nguyen PL. Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk? Urology 2014. PubMed
  • Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res 2014; 20:1873-83. PubMed
  • Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer 2014; 12:130-7. PubMed
  • Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014; 65:723-30. PubMed
  • Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma. Eur Urol 2014. PubMed
  • Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK. First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer 2014. PubMed
  • Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK. Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. Clin Genitourin Cancer 2014. PubMed
  • Khambati HK, Choueiri TK, Kollmannsberger CK, North S, Bjarnason GA, Vaishampayan UN, Wood L, Knox JJ, Tan MH, Mackenzie MJ, Donskov F, Rini BI, Heng DY, . Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clin Genitourin Cancer 2014. PubMed
  • McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014; 65:577-84. PubMed
  • Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 2014; 120:711-21. PubMed
  • McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK. Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma. Eur Urol 2014. PubMed
  • Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs 2014; 32:178-87. PubMed
  • Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R. Kidney cancer, version 2.2014. J Natl Compr Canc Netw 2014; 12:175-82. PubMed
  • Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev 2013; 40:190-6. PubMed
  • Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. Eur Urol 2014. PubMed
  • Sun M, Karakiewicz PI, Sammon JD, Sukumar S, Gervais MK, Nguyen PL, Choueiri TK, Menon M, Trinh QD. Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. BMJ Open 2014; 4:e003921. PubMed
  • Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. PLoS ONE 2014; 9:e116101. PubMed
  • Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE. Identification of ALK gene alterations in urothelial carcinoma. PLoS ONE 2014; 9:e103325. PubMed
  • Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. 2015; 14:138. PubMed
  • Sonpavde G, Choueiri TK. Precision medicine for metastatic renal cell carcinoma. Urol Oncol 2013; 32:5-15. PubMed
  • Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer 2013; 11:495-500. PubMed
  • McKay RR, Taplin ME, Choueiri TK. Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. Hematol Oncol Clin North Am 2013; 27:1261-83, ix. PubMed
  • Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Hu JC, Nguyen PL. Marital status and survival in patients with cancer. J Clin Oncol 2013; 31:3869-76. PubMed
  • Kowalczyk KJ, Harbin AC, Choueiri TK, Hevelone ND, Lipsitz SR, Trinh QD, Tina Shih YC, Hu JC. Use of surveillance imaging following treatment of small renal masses. J Urol 2013; 190:1680-5. PubMed
  • Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res 2013; 19:5218-26. PubMed
  • Vickers MM, Al-Harbi H, Choueiri TK, Kollmannsberger C, North S, MacKenzie M, Knox JJ, Rini BI, Heng DY. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013; 11:311-5. PubMed
  • Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J. Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. Eur Urol 2013. PubMed
  • Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722-31. PubMed
  • Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119:2999-3006. PubMed
  • Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy 2013. PubMed
  • Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives. Trends Cardiovasc. Med. 2013; 23:104-13. PubMed
  • Kapadia S, Hapani S, Choueiri TK, Wu S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol 2013. PubMed
  • Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 2013; 63:717-23. PubMed
  • Kowalczyk KJ, Choueiri TK, Hevelone ND, Trinh QD, Lipsitz SR, Nguyen PL, Lynch JH, Hu JC. Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int 2013. PubMed
  • Choueiri TK, Je Y, Cho E. Analgesic use and the risk of kidney cancer: A meta-analysis of epidemiologic studies. Int J Cancer 2013. PubMed
  • Choueiri TK, Pomerantz MM, Signoretti S. Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol 2013; 14:105-7. PubMed
  • Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14:141-8. PubMed
  • Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, Bellmunt J, Choueiri TK. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2013. PubMed
  • Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31:181-6. PubMed
  • Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY, . The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013. PubMed
  • Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol 2013; 14:81-7. PubMed
  • Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology 2012; 81:130-4. PubMed
  • Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. Journal of the National Cancer Institute 2012; 104:1837-40. PubMed
  • Joh HK, Cho E, Choueiri TK. ABO blood group and risk of renal cell cancer. 2012; 36:528-32. PubMed
  • Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. J Clin Oncol 2012. PubMed
  • Choueiri TK, Cheng S, Qu AQ, Pastorek J, Atkins MB, Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)☆ Urol Oncol 2013. PubMed
  • Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S. BRAF mutations in metanephric adenoma of the kidney. Eur Urol 2012; 62:917-22. PubMed
  • Klempner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D, Atkins MB. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J Clin Oncol 2012; 30:e264-8. PubMed
  • Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 2012; 13:927-35. PubMed
  • Ulmer WD, Prasad SM, Kowalczyk KJ, Gu X, Dodgion C, Lipsitz S, Palapattu GS, Choueiri TK, Hu JC. Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol 2012; 188:775-80. PubMed
  • Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48:1519-24. PubMed
  • Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, Rini BI. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010; 116:5400-6. PubMed
  • Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE, Hu JC. Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. J Clin Oncol 2011. PubMed
  • Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O. RET protein expression in papillary renal cell carcinoma. Urol Oncol 2011. PubMed
  • Williams SB, Gu X, Lipsitz SR, Nguyen PL, Choueiri TK, Hu JC. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer 2011. PubMed
  • Parithivel K, Ramaiya N, Jagannathan JP, O'Regan K, Krajewski K, Fisher D, Choueiri TK, Jacobsen E. Everolimus- and Temsirolimus-Associated Enteritis: Report of Three Cases. J Clin Oncol 2011. PubMed
  • Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011; 185:439-44. PubMed
  • Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK. Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Advanced Renal Cell Ca Eur Urol 2011. PubMed
  • Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, Choueiri TK, Chowdhury S. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 2011. PubMed
  • Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA. Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab. J Clin Oncol 2011. PubMed
  • Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized Trials. J Urol 2010; 185:116-20. PubMed
  • Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2010; 185:60-6. PubMed
  • Schutz FA, Je Y, Choueiri TK. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials. Crit Rev Oncol Hematol 2011. PubMed
  • Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD. Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor-Signaling Inhibitors. Hypertension 2010; 56:1131-6. PubMed
  • Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, Rini BI, Choueiri TK. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2010. PubMed
  • Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Cin PD, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010; 116:5219-25. PubMed
  • Katz L, Choueiri TK, Bellmunt J. 孫孫C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. BJU Int 2010; 106:1249-50. PubMed
  • Ahove DA, Hoffman KE, Hu JC, Choueiri TK, D'Amico AV, Nguyen PL. Which Patients With Undetectable PSA Levels 5 Years After Radical Prostatectomy Are Still at Risk of Recurrence?-Implications for a Risk-adapted Follow-up Strategy. Urology 2010; 76:1201-5. PubMed
  • Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study☆ Urol Oncol 2010. PubMed
  • Choueiri TK, D'Amico AV, Chen MH. Reply to impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010. PubMed
  • Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D'Amico AV. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010; 106:979-85. PubMed
  • Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010; 106:772-8. PubMed
  • Kelly PJ, Weiss SE, Sher DJ, Perez-Atayde AR, Dal Cin P, Choueiri TK. Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. J Clin Oncol 2010; 28:e433-5. PubMed
  • Choueiri TK, Schutz FA, Je Y. Reply to D.R. Minor. J Clin Oncol 2010. PubMed
  • Hu JC, Prasad SM, Gu X, Williams SB, Lipsitz SR, Nguyen PL, Choueiri TK, Choi WW, D'Amico AV. Determinants of Performing Radical Prostatectomy Pelvic Lymph Node Dissection and the Number of Lymph Nodes Removed in Elderly Men. Urology 2010. PubMed
  • Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY. Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. Urology 2010; 76:430-4. PubMed
  • Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV. Risk of All-Cause and Prostate Cancer-Specific Mortality After Brachytherapy in Men with Small Prostate Size. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol 2010. PubMed
  • Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28:2280-5. PubMed
  • Swinburn P, Lloyd A, Nathan P, Choueiri TK, Cella D, Neary MP. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin 2010; 26:1091-6. PubMed
  • Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 2010; 105:1247-54. PubMed
  • Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2010. PubMed
  • Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010; 116:1887-92. PubMed
  • Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE. Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens. J Clin Oncol 2010; 28:1850-5. PubMed
  • Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer 2010; 116:610-5. PubMed
  • Choueiri TK. Prognostic factors in patients treated with VEGF-targeted therapies. Clin Adv Hematol Oncol 2010; 8:92-3. PubMed
  • Choueiri TK, Atkins MB. Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit? Nat Rev Clin Oncol 2009; 6:679-80. PubMed
  • Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794-9. PubMed
  • Bellmunt J, Rosenberg JE, Choueiri TK. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol 2009; 56:606-8. PubMed
  • Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10:967-74. PubMed
  • Choueiri TK, Mosquera JM, Hirsch MS. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer 2009; 7:E93-4. PubMed
  • Wiklund F, Tretli S, Choueiri TK, Signoretti S, Fall K, Adami HO. Risk of bilateral renal cell cancer. J Clin Oncol 2009; 27:3737-41. PubMed
  • Choueiri TK, Bellmunt J. Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncol 2009; 10:740. PubMed
  • Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin 2009; 25:2081-90. PubMed
  • Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 2009; 7:659-65. PubMed
  • Medioni J,Choueiri TK,Zinzindohoue F,Cho D,Fournier L,Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J Urol 2009; 181:2470-5; discussion 2475. PubMed
  • Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw 2009; 7:672-93. PubMed
  • Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009; 7:618-30. PubMed
  • Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. Treatment selection for patients with metastatic renal cell carcinoma. Cancer 2009; 115:2327-33. PubMed
  • Courtney KD,Choueiri TK. Optimizing recent advances in metastatic renal cell carcinoma. Curr Oncol Rep 2009; 11:218-26. PubMed
  • Chowdhury S,Choueiri TK. Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev Anticancer Ther 2009; 9:373-9. PubMed
  • Choueiri TK,Xie W,D'Amico AV,Ross RW,Hu JC,Pomerantz M,Regan MM,Taplin ME,Kantoff PW,Sartor O,Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009; 115:981-7. PubMed
  • Chowdhury S,Harper PG,Choueiri TK. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. Nat Clin Pract Oncol 2008; 5:698-9. PubMed
  • Hu JC,Hevelone ND,Ferreira MD,Lipsitz SR,Choueiri TK,Sanda MG,Earle CC. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol 2008; 180:1969-74. PubMed
  • Rini BI,Choueiri TK,Elson P,Khasawneh MK,Cotta C,Unnithan J,Wood L,Mekhail T,Garcia J,Dreicer R,Bukowski RM. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1309-14. PubMed
  • Choueiri TK,Vaziri SA,Jaeger E,Elson P,Wood L,Bhalla IP,Small EJ,Weinberg V,Sein N,Simko J,Golshayan AR,Sercia L,Zhou M,Waldman FM,Rini BI,Bukowski RM,Ganapathi R. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008; 180:860-5; discussion 865-6. PubMed
  • Choueiri TK,Raghavan D. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. Nat Clin Pract Oncol 2008; 5:444-54. PubMed
  • Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008; 9:658-71. PubMed
  • Choueiri TK, Baz RC, McFadden CM, Khasawneh M, Karam MA, Kelly M, Hussein MA. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int 2007; 101:712-5. PubMed
  • Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 2008; 179:906-10; discussion 910. PubMed
  • Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-31. PubMed
  • Escudier B, Choueiri TK, Oudard S, Szczylik C, N. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007; 178:1901-5. PubMed
  • Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R, Zhou M. Differential expression of caveolin-1 in renal neoplasms. Cancer 2007; 110:776-82. PubMed
  • Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110:543-50. PubMed
  • Choueiri TK, Stephenson AJ, Gilligan T, Klein EA. Management of clinical stage I nonseminomatous germ cell testicular cancer. Urol Clin North Am 2007; 34:137-48; abstract viii. PubMed
  • Choueiri TK, Rini B, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol 2006; 18:249-55. PubMed
  • Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006; 107:2609-16. PubMed
  • Hicks DG, Yoder BJ, Short S, Tarr S, Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Cicek M, Choueiri TK, Tubbs RR, Gaile D, Nowak N, Accavitti-Loper MA, Frost AR, Welch DR, Casey G. Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res 2006; 12:6702-8. PubMed
  • Choueiri TK, Bukowski RM, Rini BI. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol 2006; 33:596-606. PubMed
  • Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol 2006; 17:860-5. PubMed
  • Choueiri TK, Wesolowski R, Mekhail TM. Phenoxodiol: isoflavone analog with antineoplastic activity. Curr Oncol Rep 2006; 8:104-7. PubMed
  • Choueiri TK, Hutson TE, Bukowski RM. Evolving role of pegylated interferons in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2003; 3:823-9. PubMed
  • Abou-Jawde R, Choueiri T, Alemany C, Mekhail T. An overview of targeted treatments in cancer. Clin Ther 2003; 25:2121-37. PubMed
  • Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, Choueiri TK. Prospective evaluation of analgesic use and risk of renal cell cancer. J Clin Oncol 2010.
  • Harshman LC, Choueiri TK, Drake C, Stephen Hodi F. Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014; 20:272-80. PubMed
  • Regan MM, Brick AJ, Choueiri TK, Clement JM, Kwabi C, Shah K, Amato A, McDermott DF, Atkins MB, Signoretti S. Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy J Clin Oncol 2008.
Hide